Free Trial
NASDAQ:PCVX

Vaxcyte Q2 2023 Earnings Report

Vaxcyte logo
$36.24 +0.46 (+1.29%)
Closing price 04:00 PM Eastern
Extended Trading
$36.24 +0.00 (+0.01%)
As of 04:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vaxcyte EPS Results

Actual EPS
-$0.70
Consensus EPS
-$0.74
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Vaxcyte Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vaxcyte Announcement Details

Quarter
Q2 2023
Time
After Market Closes
Conference Call Date
Tuesday, August 8, 2023
Conference Call Time
4:00PM ET

Upcoming Earnings

Vaxcyte's Q2 2025 earnings is scheduled for Tuesday, August 5, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Vaxcyte Earnings Headlines

Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve suffered financial hardship…Our President may have solved everything.
Vaxcyte: Sentiment Is Pushing The Shares Down
See More Vaxcyte Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vaxcyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vaxcyte and other key companies, straight to your email.

About Vaxcyte

Vaxcyte (NASDAQ:PCVX) (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of next-generation vaccines designed to prevent infectious diseases globally. Founded in 2017 and headquartered in San Carlos, California, Vaxcyte leverages its proprietary vaccine design platform, which incorporates genomic and immunological data to identify novel antigens and optimize immunogenicity. The company’s approach integrates advanced bioinformatics, protein engineering and cutting-edge manufacturing techniques to advance vaccine candidates from concept to clinic more efficiently than traditional methods.

The company’s lead programs include VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV) designed to address remaining gaps in current pneumococcal disease protection, and VAX-A1, a peptide-based vaccine targeting Streptococcus pyogenes infections, which are responsible for a broad spectrum of illnesses ranging from pharyngitis to invasive disease. Both candidates have entered clinical trials, positioning Vaxcyte to expand upon the commercial successes of existing vaccines by offering broader coverage and enhanced immunological profiles. In parallel, Vaxcyte is advancing additional preclinical programs against other high-unmet-need pathogens using the same platform technology.

Vaxcyte’s leadership team is composed of vaccine development veterans with extensive experience in global regulatory affairs, clinical development and commercial strategy. John Maki, the company’s president and chief executive officer, brings more than two decades of industry expertise from roles at Janssen Vaccines and other biotech firms. The company’s board of directors and scientific advisory board feature experts in microbiology, immunology and public health, guiding the strategic direction and ensuring rigorous scientific standards across all programs.

While headquartered in the United States, Vaxcyte conducts multinational clinical trials and collaborates with contract manufacturing organizations to support global supply chain needs. The company’s strategic partnerships aim to accelerate late-stage development and prepare for broad distribution upon regulatory approval. Through its innovative platform and focused pipeline, Vaxcyte seeks to address critical gaps in vaccine coverage and deliver meaningful advancements in public health worldwide.

View Vaxcyte Profile

More Earnings Resources from MarketBeat